



Home Office

PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: **'ASRU_establishment name_PPL number_PPLh surname_date_sc18'** and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number].

Establishment Licence name	University of Cambridge – Anne McLaren Building
Establishment Licence number	X81BD37B1
Name of PPL holder	Prof. Brian Huntly
PPL number	PP3042348
Protocol no	8
Protocol title	Study of the impact of genetic alterations on HSPC function during the development, progression and treatment of blood cancers
Severity classification	Moderate
1. Date of incident	04/02/2024
2. Species	Mouse

3. Brief details of study and how the limits or constraints have been breached	To study the effects of therapeutics on the treatment of leukaemia. Specifically in single treatment or combination. The mice have been treated with drugs, either in combination or a single treatment following initiation of leukaemia (through I.P injection of leukemic spleen cells). The mice are assessed for development of disease and culled once they either lose 15% of their weight or show signs of ill-health (piloerection, hunching, reduced activity) that persist for more than 6 hours. The mice are checked daily and weighed weekly. A mouse was found dead on Sunday 4th February. The mouse was last weighed on Friday 2nd February and a consistent weight was seen, with no weight loss. This mouse was treated with a single agent (Fludarabine).
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	I have spoken with the animal technicians and will speak to seniors regarding this study.
5. Cause of Problem, if known	The mouse has been dissected and spleen taken for analysis. The cause of the death is due to the leukemic burden developing in the mouse. There are 30 mice that have been injected with this tumour and of those 8 are remaining. This is the first death that has been taken place.
6. Action that has been or will be taken <i>(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)</i>	The remaining 8 mice from this tumour group will be monitored closely. The study will continue to observe for signs of ill health with regular weighing.
7. Reported by (name)	Andrew Moore (IB44D063A)

8. Date	05/02/2024
---------	------------

*****For official use*****

Inspector's comments and recommendations:

Comments and recommendations	Thank you for submitting this notification and thereby complying with standard condition 18 of your project licence. The content of this SC18 report has been read by an ASRU Inspector and this matter is now CLOSED. However, the following points should be taken into consideration: tumour burden can sometimes result in weight gain rather than loss(depending on organ /infiltration/model type).I note that this animal was said to have had a 'consistent weight' .If the spleen was enlarged then this could have accounted for that and you may need to consider tumour burden and weight gain(as well as loss) if this becomes more than an isolated occurrence. Please do inform us of any other related incidents should they occur.
Inspector name	Dr Lynda Noddings
Date	14/02/2024